[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypogonadism-ovarian\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypogonadism-ovarian":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100557927","phase-4-determining-dose-equivalence-between-oral-and-transdermal-estrogen-treatment-in-women-with-turner-syndrome-100557927",false,"NCT06544473","Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome","Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome - A Randomized Study","Inclusion Criteria:\n\n* Diagnosis of TS regardless of karyotype\n* Age 18-50 years\n* Already receiving estrogen treatment\n\nExclusion Criteria:\n\n* Active systemic chronic diseases\n* Known or suspected breast cancer\n* Known or suspected estradiol-dependent tumors (endometrial cancer or similar)\n* Untreated endometrial hyperplasia\n* Current or previous venous thromboembolism\n* Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more\n* Known hypersensitivity to the medications used\n* Pregnancy","FEMALE","18 Years","50 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This 5-week, phase IV randomized crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The objective is to establish the equipotency between the two estradiol regimens by evaluating various estradiol-dependent surrogate markers. The study involves 50 women with TS, aged 18-50 years, who are randomized to receive either oral or transdermal ERT for 14 days, followed by a crossover to the alternate treatment for another 14 days, with a one-week washout period in between. Blood tests are conducted at baseline, after the first 14 days of treatment, after the washout period, and after the final 14 days of treatment. The investigators anticipate that this study will provide clinicians with a better understanding of ERT in treating women with TS.",[27,28,29,30,31],"Turner Syndrome","Hypogonadism; Ovarian","Hormone Replacement Therapy","Estrogen Replacement Therapy","Estrogen Deficiency",[33,29,30,34,35],"Turner syndrome","Estrogen treatment","Dose equipotency","RECRUITING","2024-08-22",{"date":39,"type":40},"2024-08-23","ACTUAL",{"date":42,"type":40},"2021-11-29",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"Aarhus University Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":69,"locationsCount":48},"100559924","phase-4-long-term-effects-of-oral-versus-transdermal-estrogen-replacement-therapy-in-turner-syndrome-100559924","NCT06570460","Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome","Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome - A Randomized Trial","Inclusion criteria:\n\nFor participants with TS:\n\n* Diagnosis of TS regardless of karyotype\n* Age 18-50 years\n* Already receiving estrogen treatment\n\nFor healthy controls:\n\n* Female\n* Age 18-50 years\n* Previously healthy\n* Not receiving any medication\n* Not using any form of contraceptive pills\n* No mental or psychiatric disorders\n\nExclusion criteria:\n\n* Active systemic chronic diseases\n* Known or suspected breast cancer\n* Known or suspected estradiol-dependent tumors (endometrial cancer or similar)\n* Untreated endometrial hyperplasia\n* Current or previous venous thromboembolism\n* Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more\n* Known hypersensitivity to the medications used\n* Pregnancy\n* Menopause (for the control group only)",true,{"count":20,"type":21},[24],"This 14-month, phase IV, randomized controlled crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The study's objectives are to clarify endocrine, metabolic, cardiovascular, and thromboembolic risk factors in TS after a wash-out period without estrogen (E2) treatment; compare the effects of oral versus transdermal (TD) ERT regimens; and examine the long-term effects of E2 administration via these two routes. The study involves 50 TS women aged 18-50 years and 50 control participants. TS participants are randomized to receive either oral or TD ERT for six months, followed by crossover to the alternate treatment for another six months. Prior to randomization, any existing ERT will be discontinued for a 1-month washout period. A second 1-month washout period will occur between the two 6-month treatment phases. Laboratory analyses and clinical investigations are performed after the first wash-out period, after the first six months of treatment, and after the last six months of treatment. We anticipate that this study may provide a basis for new and improved recommendations for sex hormone replacement therapy in TS.",[27,28,29,30,31],[33,62,63,34,64],"Hormone replacement therapy","Estrogen replacement therapy","Long term side effects",{"date":66,"type":40},"2024-08-26",{"date":42,"type":40},{"date":44,"type":21},{"name":46,"class":47},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":56,"sex":76,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":48},"100420885","association-between-human-immunodeficiency-virus-hiv-infection-and-male-hypogonadism-100420885","NCT04760574","Association Between Human Immunodeficiency Virus (HIV) Infection and Male Hypogonadism","Inclusion Criteria:\n\n* HIV-infected men who have sex with men\n* HIV non-infected men\n\nExclusion Criteria:\n\n* Use of testosterone supplement, anabolic steroid in the past one year.\n* History of pituitary , adrenal or gonad diseases\n* History of pituitary surgery or radiation therapy\n* History of systemic chemotherapy\n* Active opportunistic infection under treatment\n* Cancer\n* Severe hepatic, renal or cardiac impairment","MALE","20 Years",{"count":79,"type":21},1200,"10 Years","OBSERVATIONAL","Cross-sectional study investigating the prevalence of hypogonadism in HIV-infected MSM population",[28],"2021-03-01",{"date":86,"type":40},"2021-03-03",{"date":88,"type":40},"2021-02-02",{"date":90,"type":21},"2030-11",{"name":92,"class":47},"National Taiwan University Hospital"]